RESULTS FOR : 'Biomarkers'
Showing 1 to 16 of 16 results |    
Keyword Search
Results Category/Section
Microfluidics, Circulating Biomarkers & Exosomes Asia 2020

Dates: 14-15 September 2020 Venue: Seoul, Korea

Understanding the strategic importance of BIOMARKERS for the discovery and early development phases

Biomarkers have become an increasingly hot topic in the pharmaceutical industry. How much of this is hype, how much is reality? In the overwhelming majority of cases, biomarker studies can only provide preliminary data.

Using Syngeneic Models for the Discovery of Combination Therapy Targets & Predictive Biomarkers of Immunotherapy Efficacy

Optimal treatment for any disease is one that can cure or prevent spreading with minimal impact on the patient’s quality of life.

Automating The Drive Towards Personalised Medicine

Interest in personalised medicine continues to grow, and epigenetic biomarkers are very informative in this respect, giving a clear indication of whether (and how) a patient’s gene expression profile has changed, as well as the rate of disease progression.

Could The Keys To Precision & Personalised Medicine Be Rooted In Predictive Safety & Research Methods?

To meet the massive challenges of future healthcare, perhaps no two facets hold greater promise than biomarkers for precision medicine and systems biology for personalised patient care.

Biomarker Discovery: The Need For New Generation Peptide-Protein Microarrays

The progression from health to disease is marked by significant biological changes within an individual (1).

Collaborative Research Leads To New Understanding Of Biomarkers

A new collaborative research paper sheds light on the way antibodies distinguish between different but closely related ‘biomarkers’ – in this case protein fragments which reveal information about the condition of the human body. This new understanding could enable pharmaceutical companies to develop new technologies for quickly diagnosing and treating fatal diseases.

Utilising Biomarkers to Eliminate Drug Candidates with Cardiotoxicity in Preclinical Development

The rapidly escalating costs of drug development is causing the biopharmaceutical industry to focus its R&D efforts on identifying new technologies and methods that can predict the safety and efficacy of new compounds as early as possible in the drug development process.

Using autoantibody biomarker panels for improved disease diagnosis.

Molecular biomarkers that define a particular state or condition are a powerful tool used to diagnose disease, highlight patients with a pre-disposition towards a given disease and to identify those who would benefit from a given therapy.

Business strategy for implementation of biomarkers in drug development

With pharmacoproteomic biomarkers being the subject of focus among regulatory agencies as well as research institutions, many pharmaceutical companies are increasing their interest and investment in biomarker strategies.

Experimental Medicine - Developing biomarkers in early discovery to bridge preclinical and clinical development

In today's pharmaceutical research and development environment a major problem is the transition of too many drugs to later stages of development with insufficient and/or inadequate information (eg efficacy, dosing), resulting in high attrition and consumption of resources.

Overview of biomarkers in disease, drug discovery and development

The pharmaceutical industry and the healthcare sector are both confronted with expensive technological innovation, escalating costs and pointed questions about productivity and efficiency. The parallels between the problems of producing new therapeutic agents and treating patients afflicted with poorly understood diseases are compelling.

The search for validated biomarkers in the face of biosystems complexity

As the pharmaceutical industry is all too well aware, the genomics and postgenomic sciences have delivered an excessive number of drug targets few of which have been well validated. Indeed, apart from a few rare exceptions, genomics and many millions of dollars in expenditure have yet to greatly impact drug development.

Biomarkers Make Their Mark on Current Research and Drug Development Trends

Biomarkers continue to become increasingly relevant in research and healthcare applications, as evidenced by the global market for products involved in their identification, validation, and use estimated at $8.3 billion in 2007 and projected to increase to $15 billion in 2010.

Ultra-sensitive measurement of protein and nucleic acid biomarkers may enable earlier disease detection and more effective therapies

The pharmaceutical industry is striving to develop effective new therapies for diseases, ranging from cancers to cardiovascular and neurodegenerative disorders to a host of metabolic, infectious and genetic conditions, and is placing emphasis on treatments related to the early detection of disease.

Next Generation Immunoassay Systems and the Revival of Protein Biomarkers

Proteins are the machinery that drive most biological processes; however, measuring their concentrations at low levels has been historically impeded by a lack of appropriately sensitive technology.